Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

Published:2018-11-20 Issue:1 Volume:18 Page:
ISSN:1471-2466
Container-title:BMC Pulmonary Medicine
language:en
Short-container-title:BMC Pulm Med

Author:

Jiang Ye,Zhang Jing,Huang Juanjuan,Xu Bo,Li Ning,Cao Lei,Zhao Mingdong

Funder

the Shanghai Municipal Health and Family Planning Commission Fund Project

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12890-018-0734-1.pdf

Reference32 articles.

1. Yomo S, Oda K. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: a retrospective analysis of 133 consecutive patients. Lung Cancer. 2018;119:120–6.

2. Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, et al. Randomized phase III study comparing Gefitinib with Erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016;34(27):3248.

3. Ostoros G, Sarosi V, Mandoky L, Pinter F, Schwab R, Petak I, et al. Effectiveness of erlotinib in lung adenocarcinomas with classic and alternative EGFR mutations detected by Roche 454 GS-FLX next-generation sequencing (NGS). J Clin Oncol. 2013;31(15).

4. Lee CN, Chen HY, Liu HE. Favorable response to Erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations. J Clin Oncol. 2010;28(7):E111–E2.

5. Fan WC, Yu CJ, Tsai CM, Huang MS, Lai CL, Hsia TC, et al. Different efficacies of Erlotinib and Gefitinib in Taiwanese patients with advanced non-small cell lung Cancer a retrospective multicenter study. J Thorac Oncol. 2011;6(1):148–55.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline;Journal of Clinical Oncology;2022-02-10

2. Antioxidant activity of erlotinib and gefitinib: theoretical and experimental insights;Free Radical Research;2022-02-01

3. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline;Neuro-Oncology;2021-12-21

4. Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review);Medicni perspektivi (Medical perspectives);2021-06-18

5. The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer;Translational Lung Cancer Research;2020-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3